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(6%) were excluded because they did not meet the inclusion criteria. The authors did not provide any details of the study sample (e.g. age and gender distribution, co-morbidities).
Study design
The analysis was based on a single-centred retrospective cohort study. All patients with ESBL-producing strains were identified by both the disk diffusion method and the E-test. The E-test method was considered the 'gold' standard. Each patient was included only once, so in instances were more than one culture was taken and found to be positive, only the first was reviewed and recorded.
Analysis of effectiveness
The primary outcomes used in the analysis were: mortality due to bacteraemia, defined as death occurring within 15 days of the start of treatment and not attributable to other causes; the positive and negative predictive values (PPV and NPV, respectively) of disk diffusion and the E-test; the percentage of cases adequately treated with antibiotics; the percentage of cases inadequately treated with antibiotics; and the percentage of cases where the antibiotic treatment required adjustment.
Inadequate treatment was assumed to be therapy administered within 24 hours after blood culture to which the K. pneumoniae isolate was resistant. Treatment was considered adequate if the organism was susceptible, except when cephalosporins were used to treat ESBL. Adjusted treatment was defined as when the antimicrobial agent was altered according to the antimicrobial susceptibility test results within 48 hours after the blood culture.
the cost of the E-test when using 2 E-test strips; the cost of antimicrobial treatment administered for normal renal function (standard adult dose of 2.0g imipenen per day for 14 days); the cost of antimicrobial treatment of BSI due to a non-ESBL producing strain (2.0 g ceftriaxone daily for 14 days); and the cost of treatment using cephalosporins (5 days of ceftriaxone followed by 14 days of imipenen).
Some costs were derived from the literature, whereas the source of other costs (e.g. for disk diffusion and E-test) were not reported. The costs and the quantities were not reported separately and the authors provided summary costs for the treatment costs. Since the costs were incurred during less than 2 years, discounting was not relevant. The price year was not reported.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not included.
Currency
US dollars ($). No conversion rate from the local currency (Brazilian real) was provided.
Sensitivity analysis
No sensitivity analysis was carried out.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
Assuming adequate antimicrobial therapy in 108 patients, the total costs for each diagnostic strategy were reported for different ESBL prevalence.
For the E-test methods: when ESBL prevalence was 2%, the total cost was $37,260.36; when ESBL prevalence was 10%, the cost was $48,332.04; when ESBL prevalence was 25%, the cost was $70,475.40; and when ESBL prevalence was 52%, the cost was $110,610.20.
For the disk diffusion method, for the equivalent ESBL prevalence, the costs were: $44,484.12 at 2% prevalence; $55,555.80 at 10% prevalence; $76,420.90 at 25% prevalence; and
